Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the green light for use by the NHS in England under a managed access ...

Tools used for digging up underground plant foods, supporting the idea of a plant-based diet among early humans.